Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy: A systematic review

Thrombosis and Haemostasis

Volumn 115, Issue 1, 2016, Pages 7-24

  Vries, Minka J A ^a   van der Meijden, Paola E J ^a   Henskens, Yvonne M C ^a,b   ten Cate Hoek, Arina J ^a   ten Cate, Hugo ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bleeding; Coronary artery disease; Dual antiplatelet therapy; Prognostic tests

Indexed keywords

ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2C19;

ALGORITHM; BLEEDING; BLOOD CLOTTING PARAMETERS; CLINICAL ASSESSMENT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; CLINICAL PATHWAY; COMBINATION DRUG THERAPY; DECISION SUPPORT SYSTEM; DRUG RESISTANCE; GENETICS; GENOTYPE; METABOLISM; PHARMACOGENETICS; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ALGORITHMS; CORONARY ARTERY DISEASE; CRITICAL PATHWAYS; CYTOCHROME P-450 CYP2C19; DECISION SUPPORT TECHNIQUES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GENOTYPE; HEMORRHAGE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84951310376     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-04-0355     Document Type: Review

References (64)

1. Sorensen R, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967-1974.
2. Abraham NS, et al. Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalisations with complex antithrombotic therapy in elderly patients. Circulation 2013; 128: 1869-1877.
3. Hamm CW, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
4. Levine GN, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124: e574-651.
5. Task Force on the management of STseamiotESoC, Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
6. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
7. Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
8. Mehran R, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009; 30: 1457-1466.
9. Lamberts M, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012; 126: 1185-1193.
10. Rao SV, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200-1206.
11. Mehran R, et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterisation and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularisation and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv 2011; 4: 654-664.
12. Tantry US, Gurbel PA. Assessment of oral antithrombotic therapy by platelet function testing. Nature Rev Cardiol 2011; 8: 572-579.
13. Tantry US, et al. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to ADP Associated with Ischaemia and Bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
14. Ait-Mokhtar O, et al. High on treatment platelet reactivity. Heart Lung Circ 2012; 21: 12-21.
15. Kubica A, et al. Genetic determinants of platelet response to clopidogrel. J Thromb Thrombol 2011; 32: 459-466.
16. Campo G, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-2483.
17. Lip GY, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011; 13: 723-746.
18. Serebruany V, et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010; 31: 227-235.
19. Siller-Matula JM, et al. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer? Thromb Haemost 2015; 113: 37-52.
20. Kmet LM LR, Cook LS. Standard quality assessment Criteria for Evaluating primary Research Papers from a variety of fields. Alberta Heritage Foundation for Medical Research 2004.
21. NHS Centres for Review and Dissemination. Undertaking systematic reviewers of research of effectiveness: CRD’s guidance for those carrying out or commissioning reviews. University of York 2001; 2nd ed. York.
22. Janssen PW, ten Berg JM. Platelet function testing and tailored antiplatelet therapy. J Cardiovasc Transl Res 2013; 6: 316-328.
23. Harrison P. Advances in the monitoring of anti-P2Y12 therapy. Platelets 2012; 23: 510-525.
24. Lordkipanidze M. Advances in monitoring of aspirin therapy. Platelets 2012; 23: 526-536.
25. Mehran R, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736-2747.
26. Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J 2009; 339: b2700.
27. Soffer D, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 2003; 59: 21-25.
28. Cuisset T, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 2009; 5: 325-329.
29. Bonello L, et al. Relationship between post-treatment platelet reactivity and ischaemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 2012; 10: 1999-2005.
30. Stone GW, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382: 614-623.
31. Kirtane ASTXK. Is there a therapeutic window for platelet responsiveness among PCI patients? Analysis from the ADAPT-DES study. J Am Coll Cardiol 2013; 62: B48-49.
32. Patti G, et al. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol 2011; 107: 995-1000.
33. Huczek Z, et al. Medium on-treatment platelet reactivity to ADP is favorable in patients with acute coronary syndromes undergoing coronary stenting. Platelets 2011; 22: 521-529.
34. Mangiacapra F, et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv 2012; 5: 281-289.
35. Huczek Z, et al. Increased risk of minor bleeding and antiplatelet therapy cessation in patients with acute coronary syndromes and low on-aspirin platelet reactivity. A prospective cohort study. J Thromb Thrombol 2013; 36: 22-30.
36. Tsukahara K, et al. Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. Circulation J 2010; 74: 679-685.
37. Zhang JH, et al. Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with STelevation myocardial infarction. Thromb Res 2014; 134: 970-975.
38. Breet NJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
39. Breet NJ, et al. High on-aspirin platelet reactivity as measured with aggregationbased, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 2010; 8: 2140-2148.
40. Harmsze AM, et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogen Genomics 2012; 22: 169-175.
41. Siller-Matula JM, et al. Phenotyping vs genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost 2012; 10: 529-542.
42. Cuisset T, et al. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. Intern J Cardiol 2013; 168: 523-528.
43. Cuisset T, et al. CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovasc Interv 2012; 5: 1280-1287.
44. Grosdidier C, et al. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am J Cardiol 2013; 111: 985-990.
45. Cayla G, et al. Prasugrel monitoring and bleeding in real world patients. Am J Cardiol 2013; 111: 38-44.
46. Cuisset T, et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC Cardiovasc Interv 2013; 6: 854-863.
47. Deharo P, et al. Impact of new P2Y12 blockers on platelet reactivity and clinical outcomes after acute coronary syndrome: Insight from a large single center registry. IJC Heart Vessels 2014; 4: 188-192.
48. Parodi G, et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol 2012; 109: 214-218.
49. Gaglia MA, Jr., et al. Nuisance and alarming bleeding do not correlate with ontreatment platelet reactivity. Cardiovasc Revasc Med Mol Interv 2013; 14: 76-80.
50. Cuisset T, et al. Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. Am Heart J 2012; 164: 327-333.
51. Husted S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-1047.
52. Pare G, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363: 1704-1714.
53. Park MW, et al. Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention. Pharmacogen Genom 2013; 23: 558-562.
54. Sibbing D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-518.
55. Dai ZL, et al. Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. J Chin Integr Med 2012; 10: 647-654.
56. Wallentin L, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
57. Tang XF, et al. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol 2013; 69: 1103-1112.
58. Reny JL, et al. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 2012; 10: 1242-1251.
59. Bouman HJ, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nature Med 2011; 17: 110-116.
60. Kang YH, et al. Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients. Eur J Clin Pharmacol 2013; 69: 1511-1519.
61. Mrdovic I, et al. Simple risk algorithm to predict serious bleeding in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: RISK-PCI bleeding score. Circulation J 2013; 77: 1719-1727.
62. Aradi D, et al. Platelet function testing in acute cardiac care-is there a role for prediction or prevention of stent thrombosis and bleeding? Thromb Haemost 2015; 113: 221-230.
63. Breet NJ, et al. Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk? Netherl Heart J 2011; 19: 279-284.
64. Rodeghiero F, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8: 2063-2065.